drugset
drugset / Trial / NCT06299410

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

NCT06299410 ↗

Phase 1 Recruiting 42 enrolled Intra-Cellular Therapies, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects.

Timeline

Start
2024-04-11
Primary completion
2026-07-31
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ITI-1284 Unknown 10 mg Subcutaneous
Subject ITI-1284 Unknown 20 mg Subcutaneous

Indications

No indication recorded.